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Abstract
Niemann-Pick type C (NPC) disease is a lysosomal storage disorder characterized by the occurrence of visceral and
neurological symptoms. At present, the molecular mechanisms causing neurodegeneration in this disease are
unknown. Here we report the altered expression and/or mislocalization of the TAR-DNA binding protein 43
(TDP-43) in both NPC mouse and in a human neuronal model of the disease. We also report the neuropathologic
study of a NPC patient’s brain, showing that while TDP-43 is below immunohistochemical detection in nuclei of
cerebellar Purkinje cells, it has a predominant localization in the cytoplasm of these cells. From a functional point
of view, the TDP-43 mislocalization, that occurs in a human experimental neuronal model system, is associated
with specific alterations in TDP-43 controlled genes. Most interestingly, treatment with N-Acetyl-cysteine (NAC) or
beta-cyclodextrin (CD) can partially restore TDP-43 nuclear localization. Taken together, the results of these studies
extend the role of TDP-43 beyond the Amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD)/Alzheimer
disease (AD) spectrum. These findings may open novel research/therapeutic avenues for a better understanding of
both NPC disease and the TDP-43 proteinopathy disease mechanism.
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Introduction
Niemann-Pick disease, type C [NPC-MIM 257220;
MIM607625] is an autosomal recessive lysosomal stor-
age disorder due to mutations in NPC1 (95 % of pa-
tients) or NPC2 genes, encoding two proteins involved
in the intracellular trafficking of cholesterol and other
lipids. The deficiency of either protein leads to the ac-
cumulation of endocytosed unesterified cholesterol,
gangliosides, and other lipids within the lysosome/late
endosome compartment [1].
The clinical presentation of the disease is variable, and
the age at onset ranges from the perinatal period to
adulthood. The disease is typically characterized by
visceral and neurological symptoms. Apart from a small
group of patients presenting with a severe perinatal form,
leading to death within the first 6 months of life due to
liver or respiratory failure, most patients develop a pro-
gressive neurological disease. Indeed, NPC has been clas-
sically classified on the basis of the age at onset of the
neurological symptoms, irrespective of the age of first
symptoms [1].
Neuropathological features include meganeurite forma-
tion, extensive growth of ectopic dendrites, formation of
neurofibrillary tangles, neuroinflammation and neuroaxo-
nal dystrophy [2]. In advanced stages of the disease, neur-
onal loss is prominent, affecting particularly cerebellar
Purkinje cells [3]. At present, however, the molecular
events linking lysosomal storage and cellular damage are
not well understood.
Recently, it has been suggested that synergistic mecha-
nisms, between pathological proteins involved in neurode-
generation (beta-amyloid, tau, alpha-synuclein, TDP-43),
may help explain copathologies and individual diversity
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that are often detected in neurodegenerative conditions
[4]. In particular, TAR-DNA binding protein 43 (TDP-43),
a member of the heterogeneous nuclear ribonucleopro-
teins (hnRNPs) family [5], has emerged as a new player in
the field of neurodegenerative diseases [6]. Like many
hnRNPs, the major functional role of this protein in cellu-
lar metabolism concerns the regulation of many steps in
RNA processing [7]. In 2006, aberrantly phosphorylated
and ubiquitinated TDP-43 was identified as a main com-
ponent of the cytoplasmic neuronal inclusions in patients
affected by amyotrophic lateral sclerosis (ALS) and fronto-
temporal lobar degeneration (FTLD) [8]. More recently,
pathological TDP-43 inclusions have also been found in
other neurodegenerative disorders such as Alzheimer’s,
Parkinson’s, Huntington’s and Alexander diseases and
Perry Syndrome [9–12].
At the pathological level, it is now very clear that both
gain of toxic function of cytoplasmic aggregates and loss
of TDP-43 function in the nucleus may contribute to
disease pathogenesis [13, 14]. What is still the focus of
intensive research is the characterization of the molecular
pathways that are linked with aberrant TDP-43 aggrega-
tion. However, several recent lines of evidence indicate
that the autophagic and proteasome systems play a major
role in the clearance and intracellular localization of
TDP-43 [15–17].
Considering this evidence, it is reasonable to hypothesize
that lysosomal dysfunction might be linked with TDP-43
proteinopathy. Indeed, it has been shown that GGGGCC
intronic expansions of the C9orf72 gene, encoding a protein
involved in the regulation of the endosomal trafficking [18],
are mostly associated with the presence of TDP-43 path-
ology in disease-relevant brain regions [19]. In addition,
evidence of lysosomal impairment has been recently found
in brains from patients affected by frontotemporal lobar
degeneration (FTLD) with accumulation of TDP-43 due to
heterozygous loss-of-function mutations in the progranulin
(GRN) gene. Interestingly, a GRN loss-of-function, caused
by a homozygous 4-bp deletion in the GRN gene has been
associated with NCL11, a form of neuronal ceroid lipofusci-
nosis, in which the lysosomal storage disorder coexists with
the accumulation of phosphorylated TDP-43 in neurons.
Thus, lysosomal storage disorders and FTLD may share
common features [20].
Defective autophagy, characterized by increased autop-
hagosomal formation and slower turnover of autophago-
somes due to impaired lysosomal proteolysis, represents
a main feature of NPC pathology [21–24].
Based on this evidence, we hypothesized that TDP-43
localization/expression might be altered in NPC cells and
that these alterations may contribute to disease pathogen-
esis. Therefore, we analyzed the expression and intracellular
localization of TDP-43 both in mice and human models of
NPC disease.
Materials and methods
Mice
Npc1nih/nih mice maintained on BALB/cJ background
were obtained from heterozygous mating and genotypes
were identified at weaning by PCR on tail DNA as previ-
ously described [25]. All mice were maintained in our ani-
mal facility in accordance with the institutional (Università
la Sapienza) guidelines for the care and use of laboratory
animals. Experimental protocols and related procedures
were approved by the Italian Ministry of Public Health.
Human samples
Skin fibroblasts were obtained from 4 healthy donors
and 4 patients affected by NPC disease diagnosed at the
Regional Coordinator Centre for Rare Diseases by filipin
staining of cultured fibroblasts and genetic testing of
NPC1 and NPC2 as previously described [26]. Patient’s
genotypes are reported in Table 1. The presence of mu-
tations in cultured cells was also verified.
Brain tissue was obtained from a 61 year-old man who
died after a 30-year history of a clinically undiagnosed,
familial, neurological disorder. Molecular genetic testing
of DNA extracted from frozen brain autopsy tissue [27]
revealed two pathogenic mutations in the NPC1 gene,
in intron 14 (IVS14-2A > G) and exon 18 [c.2621A > T
(D874)].
All procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
1964 Helsinki declaration and its later amendments or
comparable ethical standards.
Informed, written consent was obtained from the patients
(who underwent skin biopsies) included in this report.
Cell culture
Fibroblasts were cultured and maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Paisley, UK)
containing 10 % fetal calf serum (FCS) and penicillin/
streptomycin, in a humidified atmosphere containing 5 %
CO2 at 37 °C.
Multipotent adult stem cells were obtained from fibro-
blasts at early passages (SKIN-MASCs) from 4 healthy
donors and 4 patients affected by NPC disease, as previ-
ously described [28]. The surface immunophenotype was
Table 1 Genotypes of patients included in the study
Patient Allele 1 Allele 2
NPC-1 c.3182 T > C (p. I1061T) c.3182 T > C (p.I1061T)
NPC-2 c.3182 T > C (p.I1061T) c.3182 T > C (p.I1061T)
NPC-3 c.2291C > T (p.A764V) c.2819C > T (p.S940L)
NPC-4 c.2800C > T (p.R934X) c.3235 T > C (p.F1079L)
The lysosomal accumulation of unesterified cholesterol was demonstrated by
filipin staining. All cells presented a classical biochemical phenotype
characterized by massive lysosomal accumulation of unesterified cholesterol
Dardis et al. Acta Neuropathologica Communications  (2016) 4:52 Page 2 of 13
determined using the following primary conjugated anti-
bodies: CD13, CD49a, CD49b, CD49d, CD90, CD73,
CD44, CD45, human leukocyte antigen-D related (HLA-
DR), CD34, and CD271 (BD Biosciences, Franklin Lakes,
NJ, USA); CD105 and kinase insert domain receptor
(KDR; Serotec, Oxford, United Kingdom); and CD133
(Miltenyi Biotec, Bergisch Gladbach, Germany). The
percentage of cells expressing all the antigens was deter-
mined by fluorescence-activated cell sorting (FACS) ana-
lysis (CyAn; Beckman Coulter, Brea, CA, USA). Properly
conjugated isotype-matched antibodies were used as nega-
tive controls.
Neuronal differentiation
SKIN-MASCs obtained after 3 passages in selective
medium, were seeded at a density of 8000 cells/cm2 into
plates (Corning) or on coverslips. The differentiation
protocol was previously described by Bergamin et al. [28].
Cells were plated in medium containing DMEM-HG with
10 % FBS (N1 medium). After 24 h the DMEM-HG was
replaced with fresh medium supplemented with 1 % of
B27 (Invitrogen), 10 ng/ml EGF (Peprotech) and 20 ng/ml
bFGF (Peprotech) (N2 medium) for 5 days. Thereafter,
cells were incubated for 72 h in DMEM-HG supple-
mented with 5 μg/ml insulin, 200 μM of indomethacin
and 0.5 mM IBMX (all from Sigma-Aldrich) without
FBS (N3 medium). The actual differentiation was deter-
mined by analyzing the expression of the neuron specific
markers, NeuN and tubulin b3.
Treatments
NPC neuronally differentiated cells were treated with
vehicle or either 100 μΜ M N-acetyl cysteine (NAC,
Sigma) or 400–800 μM 2-hydroxypropyl-b-cyclodextrin
(CD, Sigma Aldrich, Milan, Italy) for 24 h.
Histology, immunohistochemistry and
immunofluorescence
Npc1+/+ and Npc1−/− mice of postnatal days 11, 28 and
75 (PN11–75; 3 mice/genotype/age) were deeply anes-
thetized and then transcardially perfused with 4 % para-
formaldehyde (PFA) in PBS. Brains were removed, and
processed for immunohistochemical studies, according
to a previously published protocol [29], TDP-43 immu-
nostaining was performed using a rabbit polyclonal anti-
TDP-43 antibody (Proteintech, 1:200 dilution in PBS),
and then using the rabbit Vectastain Elite ABC Kit (Vector
Laboratories Inc., Burlingame, CA, USA) and peroxidase
substrate Vector VIP (Vector Laboratories Inc), according
to manufacturer’s instructions.
For immunofluorescence assays cells were fixed for
15 min in 4 % (w/v) paraformaldehyde in PBS and then
permeabilized in 0.3 % Triton X-100 in PBS for 5 min
on wet ice. After blocking with 2 % BSA in PBS, cells
were incubated overnight at 4 °C with the primary
antibodies raised against NeuN (Millipore), tubulin b3
(Covance, Inc., Princeton, NJ, USA), TDP-43 (Protein-
tech) Phospho-TDP-43 (Ser409/410 Sigma Aldritch),
TIA-1 (Santa Cruz), Lamp-1 (Santa Cruz) and p62
(MBL). Cells were then washed and incubated with
Alexa Fluor 555 or 488 labeled secondary antibody for
1 h at 37 °C. Cell nuclei were stained by Vectashield
Mountain Medium with DAPI (Vector Laboratories, Inc.,
Burlingame, CA, USA).
Images were obtained with a live cell imaging dedicated
system consisting of a Leica DMI 6000B microscope con-
nected to a Leica DFC350FX camera (Leica Microsystems,
Wetzlar, Hessen, Germany).
Preparation of nuclear and cytoplasmic fractions
Nuclear and cytoplasmic fractions were prepared as pre-
viously described [30], with few modifications. Briefly,
PN11-75 cerebella (3 mice/genotype/age) were homoge-
nized using a glass Dounce homogenizer in 10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT and protease/phosphatase inhibitor
(Roche Diagnostics, Indianapolis, IN, USA). Homoge-
nates were incubated with 0, 5 % NP-40 for 10 min on
ice and centrifuged at 600 g for 5 min at 4 C. The super-
natant (total cytoplasmic fraction) was diluted with
Laemmli buffer and the pellet (total nuclear fraction)
was resuspended in 20 mM HEPES, pH 7.9, 420 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol
and protease/phosphatase inhibitors (Roche Diagnos-
tics), extracted for 15 min on ice and cleared by centrifu-
gation at 10 000 g for 10 min. The supernatant was
finally diluted in Laemmli buffer. Protein concentration
was routinely determined using the DC Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA).
Western blot analysis
Equal amounts per lane of cytoplasmic and nuclear pro-
tein fractions were loaded on a 4-20 % gradient Mini-
Protean TGX pre-cast gel for electrophoresis (Bio-Rad
Laboratories) while total extracts were electrophoresed
on 10 % SDS–PAGE. Fractionated proteins were trans-
ferred to poly (vinylidene difluoride) membranes (Roche
Diagnostics) or nitrocellulose membrane (Biorad, Hercules,
CA, USA), respectively. After blocking, membranes were
incubated overnight at 4 °C with the primary antibody anti-
TDP-43 (Protein Tech), then washed, incubated with the
appropriate secondary antibody for 1 h at RT and devel-
oped with SuperSignal West Dura reagents (Thermo
Scientific/Pierce, Rockford, IL, USA). Sp1 and β-III
tubulin were used to assess the purity of nuclear and
cytoplasmic fractions, respectively, and as reference for
TDP-43 expression quantification. Total expression of
TDP-43 was normalized by actin levels. Blots were
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quantified by using a Gel Doc 2000 videodensitometer
(Biorad, Hercules, CA, USA).
RNA extraction, reverse transcription and quantitative
real-time PCR
Total RNA was extracted from neuronally differentiated
cells using the RNeasy Mini RNA extraction kit (Qiagen)
according to the manufacturer’s protocols. First strand
cDNA synthesis was performed with 1ug RNA using
random hexanucleotides (Invitrogen) and SuperScript III
reverse transcriptase (Invitrogen). Quantitative RT-PCR
was carried out in 15 μl reaction volume containing 1-3ul
of obtained cDNA, SsoAdvanced Universal SYBR Green
Supermix (BioRad) and gene-specific sense and anti-sense
primers. HPRT was used as an internal control for
normalization. Primer sequences are listed in Additional
file 1: Table S1.
Quantitative RT-PCR was performed in a Roche 480
LightCycler Real-Time PCR System, following the manu-
facturer’s instructions. LightCycler 480 Basic software
(Roche) utilized the second derivative maximum method
to identify the crossing point (Cp).
Neuropathologic studies
Neuropathologic studies of brain and spinal cord were
carried out in order to characterize NPC in human brain
tissues. Samples of fresh brain tissue were frozen and
stored at −80° C. The remainder of the brain and
spinal cord was fixed in 10 % buffered formalin. Fixed
tissue sections were obtained from multiple brain and
spinal cord regions and processed for histology and
immunohistochemical studies, according to a previ-
ously published protocol [31]. TDP43 immunostaining
was simultaneously performed on the cerebellum of
four control subjects.
Statistical analysis
Statistical significance was determined by Student’s t-
test, using the SPS software. p < 0.05 was considered as
statistically significant.
Results
Analysis of TDP-43 in NPC mice
The expression and subcellular localization of TDP-43
in the cerebellum of wild-type and Npc1−/− mice during
maturation and at adult age were investigated by immu-
nohistochemistry and western blot, respectively (Fig. 1a,
b). The expression of TDP-43 appeared significantly re-
duced in the cerebellum of Npc1−/− mice as early as
postnatal (PN) day 11, when neuropathological features
of the disease had not yet appeared. Because the devel-
opment of cerebellar cortex is still in progress at this
age, three distinct granule neurons (GN) populations,
consisting of proliferating, postmitotic and migrating
GNs can be easily identified. Proliferating GNs localize
in the outer part of the external granular layer (oEGL)
whereas postmitotic GNs stop in the inner part of the
EGL (iEGL) before migrating inward through the mo-
lecular layer (ML) to reach the internal granular layer
(IGL), thus representing the migrating GNs. Despite a
reduction of TDP-43 expression level in Npc1−/− mice,
EGL-residing GNs of both wild-type and Npc1−/− mice
expressed higher levels of this protein compared to IGL-
residing GNs. This may indicate a burst of TDP-43 ex-
pression in concomitance with GN exit from the cell
cycle. A significant reduction of TDP-43 expression in
Npc1−/− compared to wild-type mice was also observed
in Purkinje cells (PCs) (Fig. 1a). In both GNs and PCs
TDP-43 prominently localized to the nucleus. The re-
duced expression of TDP-43 in the cerebellum of PN11
Npc1−/− mice was also assessed by western blot analysis,
observing a significant reduction of the protein level
(25–30 %) and confirming the nuclear localization of
TDP-43 (Fig1B).
A similar TDP-43 expression level reduction was ob-
served between wild-type and Npc1−/− PN28 mice (Fig. 2a
and c). At this stage, TDP-43 appeared to be particularly
abundant in PC nuclei of wild-type mice, whereas both
PCs and GNs of Npc1−/− mice displayed a reduced level of
TDP-43. A similar TDP-43 expression pattern was dis-
played by additional neuronal cell types, including basket
and stellate cells that at this age can be easily detected
within the ML.
Finally, in adult PN75 Npc1−/− mouse cerebella the ex-
pression of TDP-43 was minimally detected in any of
the neuronal cell types, including PCs, GNs, basket and
stellate cells, whereas wild-type mouse cerebella dis-
played a TDP-43 expression pattern that matched that
observed in PN28 mice (Fig. 2b and d).
These results indicate that a progressive reduction of
TDP-43 expression occurs in the cerebellum of Npc1−/−
with increasing age and is present only in the disease mice.
Analysis of TDP-43 in a human neuronal model of NPC
To extend these observations to the human disease, we
then analyzed the expression of TDP-43 mRNA and
protein, both in cultured fibroblasts and in a human
neuronal model of NPC. This model was obtained
through the differentiation of human multipoint adult
stem cells isolated from the skin (hSKIN-MASCs) of pa-
tients affected by NPC. As we have previously shown,
this neuronal model has several key features of NPC and
is therefore valuable for studying the effects of NPC dys-
function at the cellular level [28].
The levels of both mRNA and protein TDP-43 expres-
sion in NPC cells were not significantly different from
the levels detected in cells derived from normal controls
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(Additional file 2: Figure S1). However, when the intra-
cellular distribution of TDP-43 was analyzed by im-
munofluorescence, a completely different intracellular
localization of this protein was observed in NPC com-
pared to control cells. As shown in Fig. 3a, b and e, in
healthy control cells TDP-43 was confined within the
cell nuclei as previously reported by many studies, while
in most NPC-derived cells (about 73 %) a significant
amount of TDP-43 protein was localized in the cytosol,
where it showed a diffuse distribution. As expected, dif-
ferentiated cells stained positively for NeuN, a marker of
mature neurons (Fig. 3c and d). Furthermore, immuno-
staining with an antibody against the phosphorylated
form of TDP-43 showed that in NPC differentiated cells
TDP-43 mislocalization is associated with hyperpho-
sphorylation (Fig. 4a and b, upper panels).
Then, we analyzed whether the observed cytoplasmic
accumulation of TDP-43 in NPC cells is a consequence
of the autophagic build up caused by defective autop-
hagosomal efflux. However, as shown in Fig. 4 (lower
panels) TDP-43 did not colocalize with lysosomal
(LAMP-1, Fig. 4c-f) or autophagosomal (p62, Fig. 4g-j)
markers in NPC derived cells.
Another common observation with regards to TDP-43
is its ability to colocalize with stress granules (SG).
Therefore, we first evaluated whether SGs are present in
cells by immunofluorescence of differentiated cells de-
rived from healthy controls and NPC patients using the
SG marker TIA-1. While in cells derived from healthy
controls TIA-1 is completely localized within the nuclei,
in about 64 % of NPC cells it was also detected in the
cytosol (Fig. 5a, b, c). Furthermore, as shown in Fig. 5d-g,
Fig. 1 TDP-43 immunohistochemistry of cerebellum sections of wt and Npc1−/− PN11 mice (a). At higher magnification (bottom panels),
immunohistochemistry revealed a decrease of TDP-43 nuclear expression in GNs of both external granule layer (EGL) and internal granule layer
(IGL), and in Purkinje cells (arrows) of Npc1−/− mice compared to wt. b Western blot analysis of TDP-43 protein levels in nuclear and cytoplasmic
cerebellar fractions, identified by Sp1 and β-III-tubulin, respectively. Histograms indicate nuclear TDP-43 abundance (mean ± SEM), determined by
densitometry of protein bands obtained in at least 3 independent experiments (having at least three replicates for each data point) taking Sp1 as
internal reference. ** indicates P < 0.01 in Student’s t-test
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TDP-43 colocalized with TIA-1 in NPC cells indicating that
in these cells cytosolic TDP-43 localized within the SG.
In order to investigate the possible functional impact
of TDP-43 mislocalization on RNA metabolism we then
analyzed the mRNA expression of a set of genes known
to be regulated by TDP-43 and involved in neuronal sur-
vival and differentiation. The expression levels of nine
genes were analyzed by real-time Q-PCR comparing
Fig. 2 TDP-43 immunohistochemistry of cerebellum sections of wt and Npc1−/− PN28 (a) and PN75 (b) mice. At higher magnification (bottom
panels), immunohistochemistry revealed a decrease of TDP-43 nuclear expression in Purkinje cells (arrows) and GNs of Npc1−/− compared to wt
mice, which is particularly pronounced in PN75 mice. ML: molecular layer; IGL: inner granule layer. (c and d) Western blot analysis of TDP-43
protein levels in nuclear and cytoplasmic cerebellar fractions, identified by Sp1 and β-III-tubulin, respectively. Histograms indicate nuclear TDP-43
abundance (mean ± SEM), determined by densitometry of protein bands obtained in at least 3 independent experiments (having at least three
replicates for each data point) taking the Sp1 as internal reference. * indicates P < 0.05 and ** indicates P < 0.01 in Student’s t-test
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normal vs. NPC-derived cells (Fig. 6). Importantly, we
observed that six of the nine genes analyzed (FAP2A,
CNTFR, MAF2D, MADD, TLE1, and TNIK) were differ-
entially expressed in cells derived from NPC patients
compared to healthy controls.
Since SGs are highly dynamic structures that disas-
semble when the stress stimuli vanish, we also analyzed
whether the intracellular localization of TDP-43 could
be restored by treating NPC cells with N-Acetyl-cysteine
(NAC), a well known anti-oxidant agent, or with 2-hy-
droxypropyl-b-cyclodextrin (CD), a cholesterol sequester-
ing agent that mobilizes cholesterol from the late
endosomal/lysosomal compartment. As shown in Fig. 7,
both agents almost completely restored TDP-43 localization
to the nucleus.
Analysis of TDP-43 expression/distribution in human NPC
brain tissue
In order to correlate the results obtained both in the
NPC mouse and in the neuronal model of the disease,
the expression and localization of TDP-43 was analyzed
in brain tissue obtained from a NPC patient carrying
mutations c.2621A > T (D874V) and IVS14-2A > G in
the NPC1 gene (Additional file 3: Figure S2).
Atrophy was prominent in cingulate cortex and cere-
bellum. Neurons with swollen perikarya contained a pale
granular material, a finding consistent with what is ob-
served in storage diseases. Evidence of neuronal storage
was noted in the cerebral cortex, hippocampus, amyg-
dala, several deep telencephalic and brain stem nuclei as
well as in the spinal cord. Tau-immunoreactive neurons
and neurofibrillary tangles were present in hippocampus
and entorhinal cortex. Tau-immunopositive threads were
also noted in the spinal cord. Amyloid-β deposits were
not present.
The normal nuclear pattern of TDP-43 immunoposi-
tivity was confirmed in multiple brain areas, including
the cerebellar dentate nucleus (Fig. 8a). However, in the
cerebellar cortex, numerous Purkinje cells lacked nuclear
TDP-43 labelling. In fact, many Purkinje cells showed
Fig. 3 Intracellular localization of TDP-43 (labeled in green) in neuron-like cells obtained from wt (a) and NPC patients (b). Immunofluorescence
showed diffuse cytosolic distribution of TDP-43 in NPC neuronal-like cells (indicated by arrows) while in wt cells TDP-43 was confined to the
nucleus. The actual neuronal differentiation of cells was confirmed by immunofluorescence using the neuronal marker NeuN (labeled in red)
(c-d). e Quantitative evaluation of the percentage of neuron like cells displaying cytoplasmic localization of TDP-43 in wt (n = 4) and NPC
patients (n = 4). At least 400 cells have been counted for each cell line. Data are presented as mean ± SD of 3 independent experiments.
**p < 0.01 in Student’s t test
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Fig. 4 Immunofluorescence of phospho-TDP-43 (labeled in red) in wt (a) and NPC (b) neuron-like cells. TDP-43 immunostaining using a phospho-
specific anti-TDP43 antibody showed the cytosolic accumulation of phosphor-TDP-43 in NPC neuronal-like cells. c-f Co-Immunofluorescence of TDP-43
(labeled in green) and the lysosomal marker LAMP-1 (labeled in red). g-j Co-Immunofluorescence of TDP-43 (labeled in green) and the autophagic
marker p62 (labeled in red). Immunostaining showed that neither LAMP-1 or p62 co-localized with TDP-43. Nuclei were stained with DAPI (blue)
Fig. 5 a Immunofluorescence of the stress granule marker TIA-1 in wt (a) and NPC (b) neuron-like cells. Arrows indicate the cytosolic localization
of stress granules in NPC cells. c Quantitative evaluation of the percentage of neuron like cells displaying cytoplasmic localization of TIA- in wt
(n = 4) and NPC patients (n = 4). At least 400 cells have been counted for each cell line. Data are presented as mean ± SD of 3 independent
experiments. **p < 0.01 in Student’s t test. d-g Co-immunofluorescence of TIA-1 and TDP-43 in NPC neuronal-like cells. Arrows indicate colocalization.
Nuclei were stained with DAPi (blue)
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diffuse TDP-43-immunopositive cytoplasmic labelling with
concurrent loss of nuclear TDP43 within the same cells
(Fig. 8b). In contrast, the TDP43 immunostaining of
cerebellum from 4 control subjects revealed TDP43 nu-
clear staining in Purkinje cells with variable degrees of
cytoplasmic staining, but the pattern of TDP43-negative
nuclei with TDP43-positive cytoplasmic staining was not
observed (Fig. 8c and d). No phospho-TDP43 positive ag-
gregates were identified in cerebrum or cerebellum from
the NPC brain (data not shown).
Fig. 6 mRNA expression levels of genes regulated by TDP-43 in wt (n= 4) and NPC neuron-like cells (n = 4). TDP-43 levels were express as a percentage
of wt. HPRT was used as reference gene. Data are represented as mean ± SD of at least three independent experiments. *p < 0.05
Fig. 7 Intracellular localization of TDP-43 (labeled in green) in NPC neuron-like cells. Cells were incubated for 24 h with either NAC 100 μM or CD
800 μM and TDP-43 localization was examined by immunofluorescence. a Untreated cells (NT). b NAC treatment. c CD treatment. d Quantitative
evaluation of the percentage of neuron like cells displaying cytoplasmic localization of TDP-43 in NPC patients (n = 4) untreated or treated with
NAC and CD. At least 400 cells have been counted for each cell line. Data are presented as mean ± SD of 3 independent experiments. **p < 0.01
in Student’s t test. Treatment with either NAC or CD determined a reduction of TDP-43 staining in the cytosolic compartment
Dardis et al. Acta Neuropathologica Communications  (2016) 4:52 Page 9 of 13
Discussion
In recent years, lysosomal storage diseases have become
increasingly associated with neurodegeneration and cancer
[32]. Several connections between lysosomal genes and
neurodegeneration have begun to emerge [33]. Lysosomal
dysfunction has been suggested to play an important role
in the pathogenesis of several major neurodegenerative
disorders, including Parkinson disease (PD), Huntington
disease (HD), and Alzheimer Disease (AD). For example,
huntingtin processing occurs through the lysosomal-
endosomal system leading to autophagic cell death [34],
while amyloid β (Aβ) accumulation has been linked to
impairment of lysosomal degradation [35]. It has been
proposed that lysosomal dysfunction may also occur at
an early stage in AD [36].
More recently, impaired autophagy and lysosomal dys-
function have also been linked with alterations at the
level of RNA metabolism [37]. Indeed, TDP-43, an RNA
binding protein implicated in neurodegeneration, has
many connections with the autophagic and proteasomal
system, as indicated by the requirement of multivesicular
bodies for the clearance of TDP-43 aggregates within
cells [38]. Therefore, we have investigated whether TDP-43,
may contribute to the pathogenesis of NPC, a lysosomal
storage disorder characterized by impaired intracellular
lipid trafficking and autophagy.
In this work, we have shown aberrant expression and
cytoplasmic distribution of TDP-43 in the cerebellum of
a mouse model of NPC and in an in vitro human NPC
neuronal model system in which the cytoplasmic TDP-
43 is sequestered by stress granules. This TDP-43 redis-
tribution and sequestration may represent an important
link between neurodegeneration and normal biological
processing, as affected by mutations, other disease pro-
cesses, or prolonged environmental stress [39–41]. In
addition, our findings in the human NPC neuronal model
indicate that several genes reported to be under the control
of TDP-43 at the RNA processing level are aberrantly
Fig. 8 Cerebellar histologic sections immunostained with TDP43 (a-d). In the 61 year-old proband’s brain, dentate nucleus neurons show nuclear
staining (a), while Purkinje cells show cytoplasmic staining but lack nuclear staining (b). In brain sections from 60 year-old (c) and 89 year-old (d)
control subjects, Purkinje cells demonstrate nuclear staining with variable degrees of cytoplasmic staining. (polyclonal TDP43, 1:1000, Proteintech;
original magnifications ×400)
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expressed. This data suggests that the aberrant recruitment
of TDP-43 in NPC cells might be sufficient to impair its
normal function and provides a possible direct link with
the neuropathology observed in NPC. However, future
studies will be required to clarify these findings and better
define at the molecular level the exact role of TDP-43 mis-
localization in NPC pathogenesis.
In contrast to previous studies showing that p62 co-
localizes with TDP-43-positive cytoplasmic inclusions
in patients with FTLD-MND, we did not observe co-
localization of TDP-43 and p62 in NPC cells. This
finding may represent a feature specific to NPC path-
ology. A previous study showed that even though p62
co-localizes and physiologically interacts with TDP-43,
the p62 in the cerebral cortex of FTLD-TDP patients
co-immunoprecipitated a smaller amount of TDP-43
as compared with normal brains [42]. This observation
suggested that the disruption of the interaction between
these two proteins contributed to the pathology [42].
Besides accumulating cholesterol within the lysosomal
compartment, NPC cells are characterized by oxidative
stress, which may contribute to disease pathology [43,
44]. A restoration of both cholesterol trafficking and cel-
lular oxidative status resulted in the clearance of cyto-
solic TDP-43 accumulation.
Based on the reported data, it is possible to hypothesize
that in NPC, chronic stress conditions (including oxidative
stress) may trigger the translocation of TDP-43 from the
nucleus to the cytosol where it is phosphorylated and re-
cruited within stress granules. As a consequence, its func-
tion in the regulation of RNA processing may be impaired.
The presence of TDP-43 pathology has also been ob-
served in brain tissue obtained from a patient affected
by NPC. This result is in line with the findings observed
and in the human neuronal model of the disease. How-
ever, it must be interpreted with caution and confirmed
by analyzing brain tissue from additional NPC patients.
Although TDP-43 pathology was observed in both
NPC−/− mouse and in NPC human cells/tissue, the re-
sults obtained in mice do not exactly reflect the findings
in human samples, suggesting that NPC−/− mouse would
not be the best model of TDP-43 pathology in NPC. The
obtained results are not surprising considering that some
characteristic features of NPC human neurons, such us
the high degree of ectopic dendritogenesis and the pres-
ence of neurofibrillar tangles [45, 46], are not present in
mice, suggesting important specie-specific differences be-
tween mouse and human NPC neurons.
Finally, it is worth noting that in NPC cells, TDP-43
showed a diffuse cytoplasmic distribution, but no well-
formed aggregates. Recently, a similar pattern of TDP-
staining was described by Van Deerlin et al., in anterior
horn cells and other neurons in brains from ALS pa-
tients. It was suggested that this TDP43-diffuse, often
stippled or granular distribution represents a “pre-in-
clusion” state [47].
The reported findings are significant for several rea-
sons. First, they potentially expand the presence of
TDP-43 proteinopathies [6] beyond the ALS/FTD/AD
spectrum. Second, they suggest that TDP-43 might
represent a new target for the development of therapeutic
interventions for NPC. In particular, it is interesting to
note that beta-cyclodextrin, a compound currently under
clinical evaluation for the treatment of NPC can partially
restore TDP-43 nuclear localization. This observation sug-
gests that successful drugs being developed for NPC may
also find an application in the treatment of other TDP-43
proteinopathies.
Conclusions
In conclusion, these results extend the importance of
the role of TDP-43 in neurodegenerative disease and fur-
ther highlight the need to prioritize the targeting of this
protein to develop novel therapeutic strategies. Further-
more, our results suggest that metabolic diseases which
involve neuropathological consequences could represent a
novel field of study to search for alterations in RNA bind-
ing proteins, especially those that are already described to
play a role in motorneuron diseases. The reason is that
both the differences and similarities observed in the ex-
pression or regulation of these proteins in very different
cellular disease contexts, might help us to pinpoint the
basic functional alterations that trigger neurodegeneration.
In addition, confirming their eventual presence in a par-
ticular metabolic disease will also represent an advantage
with regards to future therapeutic strategies. In particular,
it is to be expected that novel therapeutic strategies that
show promise in one type of disease might also prove to
be very beneficial also in other disease contexts.
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